Have a look at Polynovo.
Current market cap of about $1.4 B and five years ago the market cap was nothing.
Their main burns product had sales of $9m last year with total revenue of $13m.
Arguably, the market for Promoarker D is significantly higher than for burns treatments .
PIQ needs actual sales and if using Promarker D becomes accepted practice for identification
of kidney problems then we know the potential is extremely high.
As an example, identifying Malaria in Tanzania is done by a simple pin prick to the finger test and it is about 83%
accurate and it is the go to test used.
Clearly, Promarker D is for a different market but it remains to be seen if it becomes accepted practice .
- Forums
- ASX - By Stock
- PIQ
- News: PIQ Proteomics International Laboratories Launches PromarkerD In Spain Under Deal With Patia...
News: PIQ Proteomics International Laboratories Launches PromarkerD In Spain Under Deal With Patia..., page-25
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PIQ (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.04 |
Change
0.010(0.98%) |
Mkt cap ! $133.5M |
Open | High | Low | Value | Volume |
$1.03 | $1.05 | $1.02 | $172.4K | 167.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6605 | $1.04 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.04 | 10776 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6605 | 1.035 |
1 | 5000 | 1.025 |
2 | 287465 | 1.020 |
1 | 20000 | 1.015 |
7 | 43463 | 1.010 |
Price($) | Vol. | No. |
---|---|---|
1.040 | 10776 | 2 |
1.045 | 442 | 1 |
1.070 | 12663 | 1 |
1.075 | 10000 | 1 |
1.080 | 7000 | 1 |
Last trade - 15.17pm 13/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.04 |
  |
Change
0.010 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
$1.04 | $1.04 | $1.02 | 15283 | ||
Last updated 15.53pm 13/05/2024 ? |
Featured News
PIQ (ASX) Chart |
The Watchlist
MGU
MAGNUM MINING AND EXPLORATION LIMITED
Neil Goodman, MD
Neil Goodman
MD
SPONSORED BY The Market Online